

Certified copy from the Benelux Register

Registration number

1510907

Number and filing date (date and time) of the application

1510907 16.09.2024 , 14.33

Expiry date

16.09.2034

Name and address of the holder

Argenx B.V.
Industriepark Zwijnaarde 7
9052 Zwijnaarde,
Belgium.

Name and address of representative or the correspondence address of the holder

GEVERS
De Kleetlaan 7 A (4de verdieping), Pegasus Park
1831 Diegem,
Belgium.

Word mark

ARGENX

Class numbers and list of goods and services

CI 05 Pharmaceuticals and medical preparations for therapeutic purposes in the field of immunology and autoimmune diseases; pharmaceutical preparations for the prevention or treatment of autoimmune, antibody-mediated, neuromuscular, hematological, inflammatory, respiratory, kidney, skin, and transplantation-related diseases and disorders, cancer and diseases of the immune system; compositions of antibodies or fragments of antibodies or derivatives of antibodies with therapeutic properties; antibodies or fragments of antibodies or derivatives of antibodies for the prevention or treatment of autoimmune, antibody-mediated, neuromuscular, hematological, inflammatory, respiratory, kidney, skin, transplantation-related diseases and disorders, cancer and diseases of the immune system

CI 35 Wholesale and retail services for therapeutic pharmaceutical preparations in the field of immunology and auto-immune diseases and antibodies or fragments or derivatives of antibodies with therapeutic properties; Administrative services in relation to patient information in the field of immunology, diseases of the immune system and antibody therapeutics; administration of patient reimbursement programs

CI 42 Research and development in the field of immunology, antibody engineering and autoimmune diseases for therapeutic purposes; therapeutic drug research and development in the field of immunology, antibody technology and autoimmune diseases; scientific and technological services and research relating to immunity, autoimmune diseases and antibody engineering for therapeutic purposes; providing medical and scientific research information in the field of therapeutic pharmaceuticals, clinical trials, research and development

CI 44 Providing information to patients in the field of auto-immune, antibody-mediated, neuromuscular, hematological, inflammatory, respiratory, kidney, skin, and transplantation-related diseases and disorders, cancer and diseases of the immune system and the treatment thereof; consultancy and information services relating to therapeutic biopharmaceutical products; Provision of information on therapeutic pharmaceutical, medical, and healthcare products to customers or patients through an online computer network

Class numbers (00 = to)

05 35 42 44

Publication date of the registration

30/11/2024

Registration date

30.11.2024

Publication date of the application

24/09/2024



The Hague, February 17, 2025

In name of the Director General
D. Wuytens